The evaluation and management of electrical storm

Texas Heart Institute Journal

Volumn 38, Issue 2, 2011, Pages 111-121

  Eifling, Michael ^a   Razavi, Mehdi ^a   Massumi, Ali ^a  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Anti arrhythmia agents therapeutic use; Cardiomyopathies complications; Catheter ablation; Death, sudden, cardiac prevention and control; Defibrillators, implantable adverse effects; Electrocardiography; Heart arrest etiology therapy; Myocardial infarction complications; Risk factors; Tachycardia, ventricular complications drug therapy physiopathology therapy; Ventricular fibrillation complications diagnosis drug therapy physiopathology therapy

Indexed keywords

ADENOSINE; AMIODARONE; ANESTHETIC AGENT; ANTIARRHYTHMIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; LIDOCAINE; PROCAINAMIDE; PROPOFOL; PROPRANOLOL;

ACUTE HEART INFARCTION; ADRENERGIC RECEPTOR BLOCKING; AORTA BALLOON; CATHETER ABLATION; CLINICAL FEATURE; CONTINUOUS INFUSION; CORNEA LESION; CORONARY ARTERY BLOOD FLOW; DEFIBRILLATOR; DIAGNOSTIC TEST; DRUG TREATMENT FAILURE; ELECTRIC SHOCK; ELECTRICAL STORM; ELECTROCARDIOGRAM; ELECTROLYTE DISTURBANCE; HEART ARRHYTHMIA; HEART ASSIST DEVICE; HEART BUNDLE BRANCH BLOCK; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; HYPOTHYROIDISM; INCIDENCE; LIVER TOXICITY; LOADING DRUG DOSE; LUNG FIBROSIS; PROGNOSIS; QRS COMPLEX; RADIOFREQUENCY ABLATION; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT INDICATION; WOLFF PARKINSON WHITE SYNDROME;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CATHETER ABLATION; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; HEART CONDUCTION SYSTEM; HUMANS; RECURRENCE; TREATMENT OUTCOME;

EID: 79955117743     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. European Heart Rhythm Association; Heart Rhythm Society, Zipes DP, Camm AJ, Borggrefe M, Buxton AE, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/ American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006;48(5): e247-346.
2. Emkanjoo Z, Alihasani N, Alizadeh A, Tayyebi M, Bonakdar H, Barakpour H, Sadr-Ameli MA. Electrical storm in patients with implantable cardioverter-defibrillators: can it be forecast? Tex Heart Inst J 2009;36(6):563-7.
3. Johansen H, Strauss B, Arnold JM, Moe G, Liu P. On the rise: the current and projected future burden of congestive heart failure hospitalization in Canada. Can J Cardiol 2003;19(4):430-5.
4. Sesselberg HW, Moss AJ, McNitt S, Zareba W, Daubert JP, Andrews ML, et al. Ventricular arrhythmia storms in postinfarction patients with implantable def ibrillators for primary prevention indications: a MADIT-II substudy. Heart Rhythm 2007;4(11):1395-402.
5. Exner DV, Pinski SL, Wyse DG, Renfroe EG, Follmann D, Gold M, et al. Electrical storm presages nonsudden death: the antiarrhythmics versus implantable defibrillators (AVID) trial. Circulation 2001;103(16):2066-71.
6. Gatzoulis KA, Andrikopoulos GK, Apostolopoulos T, Sotiropoulos E, Zervopoulos G, Antoniou J, et al. Electrical storm is an independent predictor of adverse long-term outcome in the era of implantable defibrillator therapy. Europace 2005;7(2):184-92.
7. Credner SC, Klingenheben T, Mauss O, Sticherling C, Hohnloser SH. Electrical storm in patients with transvenous implantable cardioverter-defibrillators: incidence, management and prognostic implications. J Am Coll Cardiol 1998;32(7):1909-15.
8. Zaugg CE, Wu ST, Barbosa V, Buser PT, Wikman-Coffelt J, Parmley WW, Lee RJ. Ventricular fibrillation-induced intracellular Ca2+ overload causes failed electrical defibrillation and post-shock reinitiation of fibrillation. J Mol Cell Cardiol 1998;30(11):2183-92.
9. Joglar JA, Kessler DJ, Welch PJ, Keffer JH, Jessen ME, Hamdan MH, Page RL. Effects of repeated electrical defibrillations on cardiac troponin I levels. Am J Cardiol 1999;83(2):270-2, A6.
10. Poelaert J, Jordaens L, Visser CA, De Clerck C, Herregods L. Transoesophageal echocardiographic evaluation of ventricular function during transvenous defibrillator implantation. Acta Anaesthesiol Scand 1996;40(8 Pt 1):913-8.
11. Runsio M, Bergfeldt L, Brodin LA, Ribeiro A, Samuelsson S, Rosenqvist M. Left ventricular function after repeated episodes of ventricular fibrillation and defibrillation assessed by transoesophageal echocardiography. Eur Heart J 1997;18(1):124-31.
12. Wellens HJ, Bar FW, Lie KI. The value of the electrocardiogram in the differential diagnosis of a tachycardia with a widened QRS complex. Am J Med 1978;64(1):27-33.
13. Kindwall KE, Brown J, Josephson ME. Electrocardiographic criteria for ventricular tachycardia in wide complex left bundle branch block morphology tachycardias. Am J Cardiol 1988;61(15):1279-83.
14. Brugada P, Brugada J, Mont L, Smeets J, Andries EW. A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex. Circulation 1991;83(5):1649-59.
15. Baerman JM, Morady F, DiCarlo LA Jr, de Buitleir M. Differentiation of ventricular tachycardia from supraventricular tachycardia with aberration: value of the clinical history. Ann Emerg Med 1987;16(1):40-3.
16. Villacastin J, Almendral J, Arenal A, Albertos J, Ormaetxe J, Peinado R, et al. Incidence and clinical significance of multiple consecutive, appropriate, high-energy discharges in patients with implanted cardioverter-defibrillators. Circulation 1996;93(4):753-62.
17. Brigadeau F, Kouakam C, Klug D, Marquie C, Duhamel A, Mizon-Gerard F, et al. Clinical predictors and prognostic significance of electrical storm in patients with implantable cardioverter defibrillators. Eur Heart J 2006;27(6):700-7.
18. Saksena S, Ciccone JM, Craelius W, Pantopoulos D, Rothbart ST, Werres R. Studies on left ventricular function during sustained ventricular tachycardia. J Am Coll Cardiol 1984;4(3):501-8.
19. Recurrent ventricular tachycardia. In: Josephson ME, editor. Clinical cardiac electrophysiology: techniques and interpretation. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 528.
20. Viskin S, Belhassen B. Polymorphic ventricular tachyarrhythmias in the absence of organic heart disease: classification, differential diagnosis, and implications for therapy. Prog Cardiovasc Dis 1998;41(1):17-34.
21. Dorian P, Cass D. An overview of the management of electrical storm. Can J Cardiol 1997;13 Suppl A:13A-17A.
22. Bigger JT Jr, Dresdale FJ, Heissenbuttel RH, Weld FM, Wit AL. Ventricular arrhythmias in ischemic heart disease: mechanism, prevalence, significance, and management. Prog Cardiovasc Dis 1977;19(4):255-300.
23. Roden DM. Clinical practice. Long-QT syndrome. N Engl J Med 2008;358(2):169-76.
24. Windecker S. Percutaneous left ventricular assist devices for treatment of patients with cardiogenic shock. Curr Opin Crit Care 2007;13(5):521-7.
25. Herlitz J, Bang A, Holmberg M, Axelsson A, Lindkvist J, Holmberg S. Rhythm changes during resuscitation from ventricular fibrillation in relation to delay until defibrillation, number of shocks delivered and survival. Resuscitation 1997;34(1):17-22.
26. Kohsaka S, Razavi M, Massumi A. Idiopathic ventricular fibrillation successfully terminated by radiofrequency ablation of the distal Purkinje fibers. Pacing Clin Electrophysiol 2007;30(5):701-4.
27. Haissaguerre M, Shoda M, Jais P, Nogami A, Shah DC, Kautzner J, et al. Mapping and ablation of idiopathic ventricular fibrillation. Circulation 2002;106(8):962-7.
28. Marrouche NF, Verma A, Wazni O, Schweikert R, Martin DO, Saliba W, et al. Mode of initiation and ablation of ventricular fibrillation storms in patients with ischemic cardiomyopathy. J Am Coll Cardiol 2004;43(9):1715-20.
29. Bansch D, Oyang F, Antz M, Arentz T, Weber R, Val-Mejias JE, et al. Successful catheter ablation of electrical storm after myocardial infarction. Circulation 2003;108(24):3011-6.
30. Maury P, Hocini M, Haissaguerre M. Electrical storms in Brugada syndrome: review of pharmacologic and ablative therapeutic options. Indian Pacing Electrophysiol J 2005;5(1):25-34.
31. Ohgo T, Okamura H, Noda T, Satomi K, Suyama K, Kurita T, et al. Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm 2007;4(6):695-700.
32. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in highrisk patients with Brugada syndrome. Circulation 2004;110(13):1731-7.
33. Kern KB, Elchisak MA, Sanders AB, Badylak SF, Tacker WA, Ewy GA. Plasma catecholamines and resuscitation from prolonged cardiac arrest. Crit Care Med 1989;17(8):786-91.
34. Kern KB, Ewy GA, Voorhees WD, Babbs CF, Tacker WA. Myocardial perfusion pressure: a predictor of 24-hour survival during prolonged cardiac arrest in dogs. Resuscitation 1988;16(4):241-50.
35. Paradis NA, Martin GB, Rivers EP, Goetting MG, Appleton TJ, Feingold M, Nowak RM. Coronary perfusion pressure and the return of spontaneous circulation in human cardiopulmonary resuscitation. JAMA 1990;263(8):1106-13.
36. Bourque D, Daoust R, Huard V, Charneux M. beta-Blockers for the treatment of cardiac arrest from ventricular fibrillation? Resuscitation 2007;75(3):434-44.
37. Ditchey RV, Lindenfeld J. Failure of epinephrine to improve the balance between myocardial oxygen supply and demand during closed-chest resuscitation in dogs. Circulation 1988;78(2):382-9.
38. Tsagalou EP, Kanakakis J, Rokas S, Anastasiou-Nana MI. Suppression by propranolol and amiodarone of an electrical storm refractory to metoprolol and amiodarone. Int J Cardiol 2005;99(2):341-2.
39. Anderson JL, Rodier HE, Green LS. Comparative effects of beta-adrenergic blocking drugs on experimental ventricular fibrillation threshold. Am J Cardiol 1983;51(7):1196-202.
40. Newton GE, Parker JD. Cardiac sympathetic responses to acute vasodilation. Normal ventricular function versus congestive heart failure. Circulation 1996;94(12):3161-7.
41. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986;59(3):297-309.
42. Billman GE, Castillo LC, Hensley J, Hohl CM, Altschuld RA. Beta2-adrenergic receptor antagonists protect against ventricular fibrillation: in vivo and in vitro evidence for enhanced sensitivity to beta2-adrenergic stimulation in animals susceptible to sudden death. Circulation 1997;96(6):1914-22.
43. Nademanee K, Taylor R, Bailey WE, Rieders DE, Kosar EM. Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation 2000;102(7):742-7.
44. Kodama I, Kamiya K, Honjo H, Toyama J. Acute and chronic effects of amiodarone on mammalian ventricular cells. Jpn Heart J 1996;37(5):719-30.
45. Du XJ, Esler MD, Dart AM. Sympatholytic action of intravenous amiodarone in the rat heart. Circulation 1995;91(2):462-70.
46. Kudenchuk PJ, Cobb LA, Copass MK, Cummins RO, Doherty AM, Fahrenbruch CE, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 1999;341(12):871-8.
47. Levine JH, Massumi A, Scheinman MM, Winkle RA, Platia EV, Chilson DA, et al. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group. J Am Coll Cardiol 1996;27(1):67-75.
48. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence- based review of clinical indications. JAMA 2007;298(11):1312-22.
49. Nasir N Jr, Taylor A, Doyle TK, Pacifico A. Evaluation of intravenous lidocaine for the termination of sustained monomorphic ventricular tachycardia in patients with coronary artery disease with or without healed myocardial infarction. Am J Cardiol 1994;74(12):1183-6.
50. Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation [published erratum appears in N Engl J Med 2002;347(12):955]. N Engl J Med 2002;346(12):884-90.
51. Burjorjee JE, Milne B. Propofol for electrical storm; a case report of cardioversion and suppression of ventricular tachycardia by propofol. Can J Anaesth 2002;49(9):973-7.
52. Mahajan A, Moore J, Cesario DA, Shivkumar K. Use of thoracic epidural anesthesia for management of electrical storm: a case report. Heart Rhythm 2005;2(12):1359-62.
53. Eisenach JC, Tong CY. Site of hemodynamic effects of intrathecal alpha 2-adrenergic agonists. Anesthesiology 1991;74(4):766-71.
54. Fotopoulos GD, Mason MJ, Walker S, Jepson NS, Patel DJ, Mitchell AG, et al. Stabilisation of medically refractory ventricular arrhythmia by intra-aortic balloon counterpulsation. Heart 1999;82(1):96-100.
55. Franz MR, Burkhoff D, Yue DT, Sagawa K. Mechanically induced action potential changes and arrhythmia in isolated and in situ canine hearts. Cardiovasc Res 1989;23(3):213-23.
56. Tsai FC, Wang YC, Huang YK, Tseng CN, Wu MY, Chang YS, et al. Extracorporeal life support to terminate refractory ventricular tachycardia. Crit Care Med 2007;35(7):1673-6.
57. Zanobini M, Rossi F, Bertera A, Sandano S, Costa C, Fabrizi R, et al. Cardiopulmonary support during electrophysiological procedures for ventricular tachycardias not haemodynamically tolerated. Perfusion 2003;18(2):79-82.
58. Stevenson WG, Wilber DJ, Natale A, Jackman WM, Marchlinski FE, Talbert T, et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial. Circulation 2008;118(25):2773-82.
59. Reddy VY, Reynolds MR, Neuzil P, Richardson AW, Taborsky M, Jongnarangsin K, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 2007;357(26):2657-65.
60. Kuck KH, Schaumann A, Eckardt L, Willems S, Ventura R, Delacretaz E, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet 2010;375(9708):31-40.
61. Carbucicchio C, Santamaria M, Trevisi N, Maccabelli G, Giraldi F, Fassini G, et al. Catheter ablation for the treatment of electrical storm in patients with implantable cardioverterdefibrillators: short- and long-term outcomes in a prospective single-center study. Circulation 2008;117(4):462-9.
62. Aliot EM, Stevenson WG, Almendral-Garrote JM, Bogun F, Calkins CH, Delacretaz E, et al. EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Heart Rhythm 2009;6(6):886-933.
63. Dijkman B, den Dulk K, Wellens HJ. Management of electrical instability after ICD implantation. Pacing Clin Electrophysiol 1995;18(1 Pt 2):148-51.
64. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008;359(10):1009-17.
65. Sears SF, Todaro JF, Urizar G, Lewis TS, Sirois B, Wallace R, et al. Assessing the psychosocial impact of the ICD: a national survey of implantable cardioverter defibrillator health care providers. Pacing Clin Electrophysiol 2000;23(6):939-45.
66. Kuhlkamp V, Mewis C, Mermi J, Bosch RF, Seipel L. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. J Am Coll Cardiol 1999;33(1):46-52.
67. Pacifico A, Hohnloser SH, Williams JH, Tao B, Saksena S, Henry PD, Prystowsky EN. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med 1999;340(24):1855-62.
68. Dorian P, Borggrefe M, Al-Khalidi HR, Hohnloser SH, Brum JM, Tatla DS, et al. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation 2004;110(24):3646-54.
69. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, et al. Comparison of beta-blockers, amiodarone plus betablockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA 2006;295(2):165-71.
70. Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO, et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation 2004;110(17):2591-6.
71. Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW, et al. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol 2008;52(7):541-50.
72. Pacifico A, Ferlic LL, Cedillo-Salazar FR, Nasir N Jr, Doyle TK, Henry PD. Shocks as predictors of survival in patients with implantable cardioverter-defibrillators. J Am Coll Cardiol 1999;34(1):204-10.
73. Nordbeck P, Seidl B, Fey B, Bauer WR, Ritter O. Effect of cardiac resynchronization therapy on the incidence of electrical storm. Int J Cardiol 2010;143(3):330-6.
74. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350(21):2140-50.
75. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352(15):1539-49.
76. Vanderheyden M, Mullens W, Delrue L, Goethals M, de Bruyne B, Wijns W, et al. Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. J Am Coll Cardiol 2008;51(2):129-36.